This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cerner Inks Deal to Simplify Advance Care Planning Procedure
by Zacks Equity Research
Cerner's (CERN) partners with Vynca to simplify advance care planning process, thereby enabling patients and clinicians to discuss and make critical end-of-life decisions.
Here's Why You Should Hold on to CONMED (CNMD) Stock for Now
by Zacks Equity Research
Investor confidence is high on CONMED (CNMD) stock, thanks to solid prospects.
PDCO vs. CNMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PDCO vs. CNMD: Which Stock Is the Better Value Option?
CONMED (CNMD) Q2 Loss Narrower Than Expected, Revenues Top
by Zacks Equity Research
CONMED's (CNMD) core units - General Surgery and Orthopedic Surgery - witnessed revenue decline in Q2.
Conmed (CNMD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 93.14% and 22.20%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy CONMED (CNMD) Ahead of Earnings?
by Zacks Equity Research
CONMED (CNMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Conmed (CNMD) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Conmed (CNMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Earnings Preview: Conmed (CNMD) Q2 Earnings Expected to Decline
by Zacks Equity Research
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PDCO vs. CNMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
PDCO vs. CNMD: Which Stock Is the Better Value Option?
PDCO vs. CNMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
PDCO vs. CNMD: Which Stock Is the Better Value Option?
Here's Why You Should Hold on to CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D. However, forex remains a woe.
Why Is Conmed (CNMD) Down 0.7% Since Last Earnings Report?
by Zacks Equity Research
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to benefit from broad product portfolio and persistent focus on R&D. However, forex remains a woe.
CONMED (CNMD) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
CONMED's (CNMD) first-quarter results gain from strong performance in General Surgery segment and expansion in margins.
Conmed (CNMD) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 15.91% and 2.60%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Conmed (CNMD) Q1 Earnings Expected to Decline
by Zacks Equity Research
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MMSI vs. CNMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
MMSI vs. CNMD: Which Stock Is the Better Value Option?
Want To Retire Early? Learn the Intelligent Investing Secret - March 24, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Here's Why You Should Hold on to CONMED (CNMD) Stock Now
by Zacks Equity Research
CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D. However, forex remains a woe.
Coronavirus to Weigh on These 4 Medical Stocks' Q1 Show
by Sreyoshi Mukherjee
The coronavirus pandemic likely to disrupt the first-quarter performances of players in the MedTech space.
Why Is Conmed (CNMD) Down 6.5% Since Last Earnings Report?
by Zacks Equity Research
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
XRAY vs. CNMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
XRAY vs. CNMD: Which Stock Is the Better Value Option?
XRAY or CNMD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
XRAY vs. CNMD: Which Stock Is the Better Value Option?
CONMED (CNMD) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
CONMED's (CNMD) fourth-quarter earnings gain from higher revenues and strong performance in General Surgery segment. However, high long-term debt remains a concern.
Conmed (CNMD) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 1.12% and 0.01%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?